VYGR Voyager Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1640266 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-19.8%
TTM net income YoY17.6%
TTM EPS YoY19.8%
Revenue 3-yr CAGR-45.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-450.1%
Net margin-416.3%
FCF margin-437.4%
EBITDA margin-435.3%
Returns
ROE-58.9%
ROA-44.9%
ROIC (approx.)-69.8%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets23.7%
Debt / equity0.00x
Current ratio6.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.04x
Accruals ratio2.0%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $40.37M | $80.00M |
| R&D expense | $134.67M | $127.37M |
| SG&A expense | $37.54M | $35.92M |
| Operating income | -$131.84M | -$83.29M |
| Pretax income | -$119.58M | -$64.34M |
| Income tax | $144,000 | $665,000 |
| Net income | -$119.72M | -$65.00M |
| EBITDA | -$127.78M | -$78.56M |
| EPS (basic) | -2.04 | -1.13 |
| EPS (diluted) | -2.04 | -1.13 |
| Weighted avg. shares (diluted) | 58.69M | 57.67M |
| Balance sheet | ||
| Cash & equivalents | $65.30M | $74.24M |
| Short-term investments | $131.15M | $195.32M |
| Receivables | $1.76M | $1.50M |
| Current assets | $202.69M | $276.81M |
| PP&E, net | $13.14M | $14.31M |
| Total assets | $252.28M | $393.05M |
| Current liabilities | $26.54M | $49.79M |
| Total liabilities | $56.20M | $93.29M |
| Shareholders' equity | $196.08M | $299.76M |
| Shares outstanding | 59.05M | 54.73M |
| Cash flow statement | ||
| Operating cash flow | -$132.47M | -$15.31M |
| Capital expenditure | $2.60M | $3.52M |
| Free cash flow | -$135.06M | -$18.83M |
| Investing cash flow | $125.45M | -$94.86M |
| Financing cash flow | $816,000 | $114.02M |
| Depreciation & amortization | $4.06M | $4.73M |
| Stock-based compensation | $14.79M | $14.79M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.